- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Biocon launched its GLP-1 Liraglutide (Diavorin/Vobexoryn) for diabetes and obesity in the Netherlands via partner Pharmamedic. This marks Biocon's first direct branded GLP-1 launch in the EU, significantly boosting its metabolic portfolio and market presence.